GlyGenix Therapeutics, Inc.
Dr. William L. Fodor, Ph.D. – CEO – firstname.lastname@example.org
GlyGenix Therapeutics, Inc. (GTI) is focused on treating and curing Glycogen Storage Diseases (GSDs). Our primary focus is to cure GSD type 1a, which is caused by an inherited gene mutation resulting in altered glycogen metabolism and glucose homeostasis. We are currently evaluating in vivo approaches for targeting the normal gene to the appropriate tissue, including Adeno-Associated Viral (AAV) vector mediated gene therapy. The product opportunities target unmet clinical needs and are expected to represent a significant therapeutic advance. GlyGenix Therapeutics, Inc.’s mission is focused on the development of nucleic acid molecules that compensate or correct the genetic defects that cause Glycogen Storage Disease Type 1a.
Glygenix is currently engaged in drug development research activities and together with our scientific advisors have identified a lead drug candidate and are preparing to initiate a formal GLP toxicology study that will enable an Investigational New Drug (IND) application to the FDA.
CT Employees: 1
World Employees: 1